OncoMatch/Clinical Trials/NCT05231122
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Is NCT05231122 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Anti-CD40 Agonist Monoclonal Antibody CDX-1140 and Bevacizumab for ovarian clear cell adenocarcinoma.
Treatment: Anti-CD40 Agonist Monoclonal Antibody CDX-1140 · Bevacizumab · Pembrolizumab — This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and bevacizumab with anti-CD40 CDX-1140 may decrease symptoms, prolong survival, and improve quality of life in patients with ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 status known
BRCA status must be known.
Required: BRCA2 status known
BRCA status must be known.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antibody targeting T cell checkpoint or co-stimulation pathways
Receipt of any antibody targeting T cell checkpoint or co-stimulation pathways within 4 weeks
Cannot have received: monoclonal antibody
use of any other monoclonal based therapies within 4 weeks
Cannot have received: immunotherapy
all other immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) within 2 weeks prior to the planned start of study treatment
Cannot have received: systemic anticancer therapy
Exception: hormonal therapy is allowed until the time of randomization
Has received prior systemic anticancer therapy (including investigational agents or maintenance therapy) within 28 days prior to the planned start of study treatment.
Cannot have received: immune checkpoint blockade therapy
Progression on prior immune checkpoint blockade therapy.
Cannot have received: systemic radiation therapy
Systemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks prior to the first dose of study treatment.
Cannot have received: anti-CD40 antibody
Prior therapy with any anti-CD40 antibody.
Lab requirements
Blood counts
Absolute neutrophil count (ANC): >= 1,500 /mcL. Platelets: >= 100,000 / mcL. Hemoglobin: >= 8 g/dL or 5.0 mmol/L transfusion allowed with adequate bone marrow function.
Kidney function
Creatinine clearance >= 50 mL/min.
Liver function
Total bilirubin: <= 2 X ULN except patients with Gilbert's syndrome or liver involvement, who must have a total bilirubin <= 3 mg/dL. AST and ALT: <= 2.5 X ULN OR <= 5 X ULN for participants with liver metastases. Albumin: > 2.5 mg/dL.
Absolute neutrophil count (ANC): >= 1,500 /mcL. Platelets: >= 100,000 / mcL. Hemoglobin: >= 8 g/dL or 5.0 mmol/L transfusion allowed with adequate bone marrow function. Creatinine clearance >= 50 mL/min. Total bilirubin: <= 2 X ULN except patients with Gilbert's syndrome or liver involvement, who must have a total bilirubin <= 3 mg/dL. AST and ALT: <= 2.5 X ULN OR <= 5 X ULN for participants with liver metastases. Albumin: > 2.5 mg/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Roswell Park Cancer Institute · Buffalo, New York
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify